Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 4/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12018158 | 1.00 | OPRD1 (0.56) | OPRD1OPRM1CYP3A4CYP1A2MEN1 | |
| SCHEMBL4576560 | 0.94 | OPRD1 (0.50) | OPRD1OPRM1CYP3A4CYP1A2MEN1 | |
| SCHEMBL12016528 | 0.88 | OPRD1 (0.45) | OPRD1OPRM1MEN1KMT2ALMNA | |
| SCHEMBL5300451 | 0.87 | OPRD1 (0.72) | OPRD1OPRM1CYP3A4CYP1A2MEN1 | |
| SCHEMBL4576003 | 0.87 | OPRD1 (0.43) | OPRD1OPRM1CYP3A4CYP1A2MEN1 | |
| SCHEMBL4577098 | 0.84 | OPRD1 (0.67) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL12017981 | 0.84 | OPRD1 (0.67) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL6935960 | 0.84 | OPRD1 (0.56) | OPRD1OPRM1CYP3A4CYP1A2MEN1 | |
| SCHEMBL12017980 | 0.83 | CYP3A4 (0.79) | OPRD1OPRM1CYP3A4CYP1A2MEN1 | |
| SCHEMBL4577073 | 0.83 | CYP3A4 (0.79) | OPRD1OPRM1CYP3A4CYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220601-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP, LLC | 2012-08-30 | — | — | US | claimed |
| US-20070173515-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | MOUNT COOK BIOSCIENCES, INC. (US) | 2007-07-26 | — | — | US | claimed |
| US-20210220349-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | DMK PHARMACEUTICALS CORPORATION | 2021-07-22 | — | — | US | disclosed |
| US-10973815-B2 | Delta opioid agonist mu opioid antagonist compositions and methods for treating Parkinsons disease | VERSI GROUP, LLC (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190038620-A1 | DELTA OPIOID AGONIST MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | DMK PHARMACEUTICALS CORPORATION | 2019-02-07 | — | — | US | disclosed |
| EP-3436013-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | Versi Group, LLC (US) | 2019-02-06 | — | — | EP | disclosed |
| US-10071093-B2 | Method of treating Parkinson's Disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity | VERSI GROUP, LLC (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170290823-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | DMK PHARMACEUTICALS CORPORATION | 2017-10-12 | — | — | US | disclosed |
| WO-2017173067-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | VERSI GROUP, LLC (US) | 2017-10-05 | — | — | WO | disclosed |
| US-9701645-B2 | Method of treating Parkinson's disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity | VERSI GROUP, LLC (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160200689-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP LLC (US) | 2016-07-14 | — | — | US | disclosed |
| US-7030124-B2 | Method of treating depression with delta receptor agonist compounds | ARDENT PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1469850-A1 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | Ardent Pharmaceuticals, Inc. (US) | 2004-10-27 | — | — | EP | disclosed |
| EP-1450807-A1 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | Ardent Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003057223-A9 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS INC (US) | 2004-04-29 | — | — | WO | disclosed |
| US-20030186872-A1 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | DMK PHARMACEUTICALS CORPORATION | 2003-10-02 | — | — | US | disclosed |
| US-20030144299-A1 | Method of treating depression with delta receptor agonist compounds | DMK PHARMACEUTICALS CORPORATION | 2003-07-31 | — | — | US | disclosed |
| WO-2003057223-A1 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| WO-2003037342-A1 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| US-20020052007-A1 | Diarylmethylbenzylpiperazines and corresponding halobenzyl derivatives | ENTA HOLDING LLC | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973815-B2 | Delta opioid agonist mu opioid antagonist compositions and methods for treating Parkinsons disease | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885OPRM1 3/4885CYP3A4 1116/4885 |
| US-20030144299-A1 | Method of treating depression with delta receptor agonist compounds | CHRND, CHRNE, CHRNA3 | OPRD1 9/4885OPRM1 110/4885CYP3A4 3126/4885 |
| US-20160200689-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885CYP3A4 675/4885 |
| US-20170290823-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885CYP3A4 2300/4885 |
| US-20030186872-A1 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885OPRM1 3/4885CYP3A4 804/4885 |
| US-20190038620-A1 | DELTA OPIOID AGONIST MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885OPRM1 3/4885CYP3A4 1116/4885 |
| US-20070173515-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885CYP3A4 675/4885 |
| US-10071093-B2 | Method of treating Parkinson's Disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885CYP3A4 2300/4885 |
| US-20210220349-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885OPRM1 3/4885CYP3A4 1287/4885 |
| US-20120220601-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885CYP3A4 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.